Clinical Trial Update: Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides [Phase 2]

View source ↗

Summary

Phase II study of AFM13 in relapsed/refractory CD30-positive T-cell lymphoma and transformed mycosis fungoides completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycosis Fungoides
• Peripheral T-cell Lymphoma

Drugs mentioned

• AFM13

Snippet

Sponsor: Affimed GmbH | Conditions: Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides | Phase 2 | Status: COMPLETED | Results posted: 2023-06-05